What a Hair Loss Consultation With a Dermatologist Actually Includes matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
Last November, a friend of mine named Kevin, a 31-year-old software dev in Austin, texted me a photo of his crown under harsh bathroom fluorescents. “Is this bad?” he wrote. He’d been staring at it for a week, Googling “Norwood 3 vs Norwood 3 vertex” at 1 a.m., toggling between Reddit threads and shady clinic websites. He didn’t know what a dermatologist would actually do if he walked into one’s office. Most guys don’t. That’s the gap this article is meant to fill.
The boring truth about a hair loss consultation is that it follows a surprisingly systematic process, one built around a classification system that’s remained essentially unchanged since 1975. The Norwood scale (really the Hamilton-Norwood scale, if you want to give proper credit) stages male androgenetic alopecia into seven main types with several variant subtypes. It’s the lingua franca of hair loss medicine: dermatologists use it, researchers cite it, and transplant surgeons plan around it.
This piece walks through what happens during an actual dermatology evaluation, the biology underneath it all, what treatments actually have evidence behind them, and what everything costs. Think of it as the consultation before the consultation.
Where the Norwood Scale Came From (and Why It’s Still Around)
James Hamilton published the foundational work in the Annals of the New York Academy of Sciences in 1951. His key observation was elegantly simple: men castrated before puberty didn’t develop pattern hair loss. That finding established the hormonal link and gave researchers something concrete to work with.
O’Tar Norwood built on Hamilton’s framework in a 1975 paper in the Southern Medical Journal, expanding a rough three-stage system into the seven-stage classification we still use. He also added the Type A variant, which captures the guys whose hairline retreats more or less uniformly from front to back rather than following the classic “temples plus crown” pattern.
Why hasn’t it been replaced? A newer system called BASP was proposed in 2007 and honestly has some advantages in granularity. But the Norwood scale hits a sweet spot: it captures enough natural variation to be clinically useful while being simple enough that two different dermatologists looking at the same scalp usually agree. In medicine, that kind of inter-observer reliability is worth a lot. Seventy-plus years later, it’s still the default.
The Biology in Plain Language
Pattern hair loss isn’t really about hair falling out. It’s about hair shrinking.
The engine of the process is dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha reductase. In follicles that are genetically susceptible, DHT binds to the androgen receptor in the dermal papilla and starts a slow-motion transformation across successive growth cycles. Each cycle, the growth phase (anagen) gets a little shorter, the resting phase (telogen) gets a little longer, and the dermal papilla itself shrinks. Thick terminal hairs become wispy vellus hairs. Eventually, they become nothing visible at all. Dermatologists call this follicular miniaturization. It’s the hallmark finding under trichoscopy.
The genetics are messy. Yes, the androgen receptor gene lives on the X chromosome, which is why your maternal grandfather’s hairline gets so much attention. But paternal genetics and several autosomal loci also contribute meaningfully. Family history gives you a rough compass heading, not GPS coordinates.
This biology is exactly what finasteride and dutasteride target. Finasteride blocks the type II isoform of 5-alpha reductase; dutasteride blocks both type I and type II, producing a larger reduction in scalp DHT. Both have documented effects on hair density in clinical trials.
What Actually Happens in the Exam Room
The American Academy of Dermatology’s guidelines lay out a structured evaluation that goes well beyond a dermatologist eyeballing your scalp and saying “yep, that’s thinning.”
History comes first. When did you first notice it? Is it progressive or episodic? Any new medications? Recent illness, surgery, or major stress? Dramatic weight loss in the past six months? These questions separate androgenetic alopecia from its mimics, particularly telogen effluvium (diffuse shedding after a stressor) and alopecia areata (autoimmune patchy loss).
Trichoscopy adds the resolution. Using dermoscopy on the scalp, a dermatologist can see things invisible to the naked eye: hair shaft diameter variability (caliber variability exceeding 20% is a key finding), yellow dots representing empty follicular ostia, and density differences between affected areas and the occipital donor zone. This is where the diagnosis gets confirmed rather than guessed at.
Lab work is selective, not routine. If you’re a man with classic patterned thinning, the AAD does not recommend androgen panels. The diagnosis is clinical. If the pattern is diffuse or the history suggests other causes, ferritin, TSH, vitamin D, and a complete blood count are reasonable. The point is to rule out treatable contributors, not to run everything.
Standardized photography matters more than most patients realize. Front, top, sides, and back views, taken at consistent distance and lighting with the head in a reproducible position, are what make meaningful before-and-after comparisons possible over 6 to 12 months of treatment. Without them, you’re guessing at whether anything is working.
For a more granular approach to self-staging and assessment with photographic examples, this hair loss evaluation guide provides a clinical-grade walkthrough.
What Actually Works (and What It Costs)
I’ll be blunt: the most effective time to treat pattern hair loss is before you think you need to. Once follicles are gone, medical therapy can’t resurrect them. Here’s what the evidence supports, roughly ordered by strength of data.
Finasteride 1 mg daily has the deepest evidence base. The original five-year randomized trial, published in the Journal of the American Academy of Dermatology (JAAD) in 2002, showed sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage of users in controlled trials and are generally reversible on discontinuation. Generic finasteride costs $10 to $25 per month with discount cards; branded Propecia runs $70 to $90 monthly with no clinical advantage.
Topical minoxidil 5% is FDA-approved for over-the-counter use. The mechanism isn’t fully understood (potassium channel opening, vasodilation, direct follicular effects that prolong anagen). Visible results typically appear at three to six months. Generic versions run $10 to $30 per month. Foam and solution are clinically equivalent; foam causes less scalp irritation for some users.
Low-dose oral minoxidil (0.25 to 5 mg daily) has gained traction since a 2021 multicenter safety study by Vañó-Galván et al. in JAAD tracked 1,404 patients and found a more manageable side-effect profile than the original cardiovascular dosing suggested. Periorbital edema and hypertrichosis are the most commonly reported issues. Generic cost is often under $15 monthly; the real expense is the prescribing visit ($50 to $150 through telehealth).
Dutasteride is approved for benign prostatic hypertrophy and used off-label for hair loss. Head-to-head trials show larger DHT reductions and greater hair density improvements compared to finasteride.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable results. At $500 to $1,500 per session (three to four sessions recommended in year one), first-year costs can equal or exceed a full year of combination medical therapy. They’re reasonable add-ons for selected patients, not substitutes for core treatment.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles. US pricing runs $4 to $10 per graft; a typical 2,500 to 3,500 graft case totals $10,000 to $35,000. Turkey clinics offer similar graft counts for $2,000 to $5,000, reflecting labor and overhead differences. (Quality varies wildly in both markets.) Most patients continue medical therapy afterward because the native hair surrounding transplanted follicles will keep thinning without it.
Insurance almost never covers any of this. HSAs and FSAs may cover prescribed medications and physician visits but typically exclude surgical procedures.
Lifestyle Factors: Separating Signal From Noise
The peer-reviewed literature (primarily JAAD and the International Journal of Trichology) supports a few clear conclusions about lifestyle and hair loss, and a lot of wishful thinking fails to make the cut.
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, or below 50 ng/mL when hair loss is a concern) contributes to shedding through telogen effluvium. Iron repletion in deficient patients reduces shedding. Iron supplementation in iron-replete patients does nothing for hair.
Severe acute stress can trigger telogen effluvium two to three months after the precipitating event, typically resolving within six to nine months. It won’t cause pattern hair loss on its own, but it can unmask or accelerate underlying androgenetic alopecia.
Anabolic steroid use accelerates pattern loss in genetically susceptible men through supraphysiologic androgen exposure. Some of this damage may not be fully reversible.
Diet quality matters at the margins. Severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. But modest dietary tweaks (more kale, less sugar) don’t produce visible hair benefits beyond addressing specific deficiencies. Sorry.
See also: The Impact of Automation on Small Businesses
When You Need an Actual Dermatologist, Not the Internet
Self-management is reasonable for straightforward early pattern loss. But several scenarios really do require in-person evaluation:
Sudden diffuse shedding within the past six months suggests telogen effluvium and needs workup for the underlying cause. Patchy loss with smooth, well-defined bald spots suggests alopecia areata, an autoimmune condition with a completely different treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring may signal one of the scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, CCCA), which require prompt diagnosis to prevent permanent follicular destruction. Women with hair loss plus menstrual irregularities, acne, or hirsutism need endocrine evaluation. Rapid progression in a young patient (more than one Norwood stage per year) warrants confirmation and early intervention planning. And loss that hasn’t responded to documented standard therapy over 12 months deserves reassessment.
The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for consultation. That’s a low bar, and intentionally so.
FAQs
Are hair transplants permanent? Transplanted follicles come from the genetically resistant donor zone and generally retain that resistance long-term. But the surrounding native hair may continue to thin, which is why most transplant patients stay on medical therapy afterward.
Do biotin and collagen supplements help with hair loss? The evidence supporting either supplement in patients without documented deficiency is weak. Worth knowing: biotin can interfere with several common lab tests, including thyroid function panels and troponin assays. Tell your doctor if you’re taking it.
Can stress cause permanent hair loss? Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, though it can unmask or speed up underlying pattern loss.
How fast does pattern hair loss progress? It varies enormously. Some men move through one Norwood stage every few years; others plateau for a decade or more. Age of onset, family history, and recent rate of change are the strongest predictors.
Is oral minoxidil better than topical? Low-dose oral minoxidil produces comparable effects to topical minoxidil with better adherence for many patients. The choice comes down to side-effect tolerance and patient preference, and should involve a prescribing clinician.
How accurate are AI hair-loss assessment tools? They provide reasonable orientation for self-screening but do not replace dermatologic evaluation. Best used as a starting point for understanding your likely stage and treatment options, not a diagnosis.
What Norwood stage is too late for medication? There’s no hard cutoff, but medical therapy works best at Norwood 2 through 4. By Norwood 6 or 7, significant areas have lost follicles entirely, and transplantation (if donor supply allows) becomes the primary option for restoring coverage. Medication can still slow further loss at any stage.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
